About SMAD family member 5
SMAD family member 5 (SMAD5) is a protein
from Homo sapiens identified by UniProt accession
Q99717, 465 residues long.
MolForge cross-references it against 0 known binders and
158 disease associations.
Target properties
| Protein name | SMAD family member 5 |
| UniProt accession | Q99717 |
| Gene | SMAD5 |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (158)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.33
- heel bone mineral density · score 0.29
- neurodegenerative disease · score 0.23
- high density lipoprotein cholesterol measurement · score 0.21
- sleep duration · score 0.20
- bone quantitative ultrasound measurement · score 0.20
- insomnia · score 0.17
- insomnia measurement · score 0.16
- interleukin 9 measurement · score 0.15
- neoplasm · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99717-F1 | alphafold | PREDICTED | 80.90 | — |
Amino-acid sequence (465 residues)
MTSMASLFSF TSPAVKRLLG WKQGDEEEKW AEKAVDALVK KLKKKKGAME ELEKALSSPG QPSKCVTIPR SLDGRLQVSH RKGLPHVIYC RVWRWPDLQS HHELKPLDIC EFPFGSKQKE VCINPYHYKR VESPVLPPVL VPRHNEFNPQ HSLLVQFRNL SHNEPHMPQN ATFPDSFHQP NNTPFPLSPN SPYPPSPASS TYPNSPASSG PGSPFQLPAD TPPPAYMPPD DQMGQDNSQP MDTSNNMIPQ IMPSISSRDV QPVAYEEPKH WCSIVYYELN NRVGEAFHAS STSVLVDGFT DPSNNKSRFC LGLLSNVNRN STIENTRRHI GKGVHLYYVG GEVYAECLSD SSIFVQSRNC NFHHGFHPTT VCKIPSSCSL KIFNNQEFAQ LLAQSVNHGF EAVYELTKMC TIRMSFVKGW GAEYHRQDVT STPCWIEIHL HGPLQWLDKV LTQMGSPLNP ISSVS
Explore SMAD family member 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets